Waltham, MA – March 26, 2014 (Booth # 1343) – Corindus Vascular Robotics, the leader in precision vascular robotics, will showcase its FDA-cleared CorPath System at the upcoming American College of Cardiology (ACC) annual meeting, March 29 – 31 in Washington, D.C. The CorPath is the first medical device to bring robotic precision and accuracy to coronary angioplasty to help optimize clinical outcomes. Corindus representatives will be onsite to conduct demos of the CorPath System and answer questions about the significant advantages in procedure precision and improvements in clinical outcomes made possible by robotics in the cath lab.

Drug-eluting stents may be as safe a choice as bare metal stents when followed by a blood thinning regimen tailored to individual patients, based on the results of a research letter published March 31 in the JAMA.

Although previous research suggested that metformin may preserve left ventricular ejection fraction (LVEF) after STEMI, research presented March 31 at the American College of Cardiology (ACC) scientific session in Washington, D.C., found metformin did not improve LVEF in post-STEMI nondiabetic patients after they underwent PCI.

WASHINGTON, D.C.—Wasn’t that special? Dana Carvey, of Saturday Night Live, fame treated attendees at the American College of Cardiology (ACC) scientific session in Washington, D.C., to an acceptance speech that was part roast and part comedy show on March 29.

Christiana Care Health System is one of a handful of institutions in the region to participate in ABSORB III, the first clinical trial in the United States of an absorbable vascular scaffold for patients with coronary artery disease.

The New York Times reports that nitroglycerine, the go-to drug in emergency rooms when physicians suspect an MI, may face intermittent shortages, according to its sole supplier.

Interventional cardiologists who participated in a 90-minute course that emphasized radiation safety principals reduced patient radiation dose by 48 percent in diagnostic catheterizations.

Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC(tm)) technology for clinical diagnostics and scientific discovery, yesterday presented new data at the American Heart Association Epidemiology and Prevention Council Conference highlighting research results using the Company's proprietary ultrasensitive Erenna® Immunoassay System in the detection of cardiac troponin-I (cTnI). The study utilized the Erenna System to measure previously undetected increases in cTnI to predict development of coronary heart disease (CHD) in the general population, independent of a variety of traditional risk factors.